Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRenJi Hospital
About this trial
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility criteria
Qualifiers
Aged ≥18 years
Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer
Subjects with at least one evaluable lesion
ECOG 0-1
Disqualifiers
Metastatic disease (Stage IV)
Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Trial design
Treatments tested in this trial
- Iparomlimab and Tuvonralimab
- Paclitaxel
- Carboplatin
Treatment groups
55 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov